Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 [Anti-VEGF therapy for neovascular age-related macular degeneration -therapeutic strategies: statement of the German Ophthalmological Society, the German Retina Society and the Professional Association of Ophthalmologists in Germany

× No keyword cloud information.

40 in total

1. [New aspects in the therapy of neovascular age related macular degeneration. Current position of the Retinological Society, the Germany Ophthalmologic Society and the Professional Union of Eye Doctors of Germany].

Authors:
Journal: Ophthalmologe Date: 2009-05 Impact factor: 1.059

2. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study.

Authors: Peter K Kaiser; David S Boyer; Alan F Cruess; Jason S Slakter; Stefan Pilz; Annemarie Weisberger
Journal: Ophthalmology Date: 2012-03-22 Impact factor: 12.079

3. Delay to treatment and visual outcomes in patients treated with anti-vascular endothelial growth factor for age-related macular degeneration.

Authors: Jonathan H Lim; Sanjeewa S Wickremasinghe; Jing Xie; Devinder S Chauhan; Paul N Baird; Luba D Robman; Gregory Hageman; Robyn H Guymer
Journal: Am J Ophthalmol Date: 2012-01-14 Impact factor: 5.258

4. Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

Authors: David M Brown; Peter K Kaiser; Mark Michels; Gisele Soubrane; Jeffrey S Heier; Robert Y Kim; Judy P Sy; Susan Schneider
Journal: N Engl J Med Date: 2006-10-05 Impact factor: 91.245

5. Subjective and functional deterioration in recurrences of neovascular AMD are often preceded by morphologic changes in optic coherence tomography.

Authors: Robert Hoerster; Philipp S Muether; Manuel M Hermann; Konrad Koch; Bernd Kirchhof; Sascha Fauser
Journal: Br J Ophthalmol Date: 2011-07-18 Impact factor: 4.638

6. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.

Authors: Jeffrey S Heier; David M Brown; Victor Chong; Jean-Francois Korobelnik; Peter K Kaiser; Quan Dong Nguyen; Bernd Kirchhof; Allen Ho; Yuichiro Ogura; George D Yancopoulos; Neil Stahl; Robert Vitti; Alyson J Berliner; Yuhwen Soo; Majid Anderesi; Georg Groetzbach; Bernd Sommerauer; Rupert Sandbrink; Christian Simader; Ursula Schmidt-Erfurth
Journal: Ophthalmology Date: 2012-10-17 Impact factor: 12.079

7. Early initial clinical experience with intravitreal aflibercept for wet age-related macular degeneration.

Authors: Philip J Ferrone; Farihah Anwar; Jonathan Naysan; Khurram Chaudhary; David Fastenberg; Kenneth Graham; Vincent Deramo
Journal: Br J Ophthalmol Date: 2014-05-02 Impact factor: 4.638

Review 8. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA).

Authors: Ursula Schmidt-Erfurth; Victor Chong; Anat Loewenstein; Michael Larsen; Eric Souied; Reinier Schlingemann; Bora Eldem; Jordi Monés; Gisbert Richard; Francesco Bandello
Journal: Br J Ophthalmol Date: 2014-09 Impact factor: 4.638

9. Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial).

Authors: Charles C Wykoff; David M Brown; Maria E Maldonado; Daniel E Croft
Journal: Br J Ophthalmol Date: 2014-02-11 Impact factor: 4.638

10. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial.

Authors: Usha Chakravarthy; Simon P Harding; Chris A Rogers; Susan M Downes; Andrew J Lotery; Sarah Wordsworth; Barnaby C Reeves
Journal: Ophthalmology Date: 2012-05-11 Impact factor: 12.079

10 in total

1. [In Process Citation].

Authors:
Journal: Ophthalmologe Date: 2015-11 Impact factor: 1.059

2. [OCT angiography for exudative age-related macular degeneration : Initial experiences].

Authors: A Lommatzsch; M-L Farecki; B Book; B Heimes; D Pauleikhoff
Journal: Ophthalmologe Date: 2016-01 Impact factor: 1.059

Review 3. [Adjuvant radiotherapy during anti-VEGF in neovascular age-related macular degeneration].

Authors: P Rating; M-A Freimuth; M Stuschke; N Bornfeld
Journal: Ophthalmologe Date: 2017-04 Impact factor: 1.059

Review 4. [Experienced quality assurance in the IVOM structural contract of the AOK‑BW : A practical example].

Authors: H Agostini; A Pfaff; V Graeff; L Hesse; F Ziemssen
Journal: Ophthalmologe Date: 2020-04 Impact factor: 1.059

Review 5. [IVOM quality assurance in Westfalen-Lippe : Structure of quality assurance and results of the pilot study Q-VERA].

Authors: J Stasch-Bouws; S M Eller-Woywod; S Schmickler; J Inderfurth; P Hoffmann; C Ohlmeyer; B Kammering; D Pauleikhoff
Journal: Ophthalmologe Date: 2020-04 Impact factor: 1.059

[Anti-VEGF therapy for neovascular age-related macular degeneration -therapeutic strategies: statement of the German Ophthalmological Society, the German Retina Society and the Professional Association of Ophthalmologists in Germany - November 2014].